$0.569
-0.011 (-1.91%)收盤時
價格預測
在 App 中開啟以解鎖更長週期的預測。
CTXR 相似圖表分析預測
Alphio's CTXR stock price prediction model matches the current Citius Pharmaceuticals Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.58 (+2.07%). The 1-week path is $0.59 (+3.35%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
該買進 Citius Pharmaceuticals Inc 股票嗎？
Citius Pharmaceuticals Inc is a good buy right now due to its recent revenue growth of $7.1 million in Q3 2026, reflecting a significant market acceptance of its product LYMPHIR. Additionally, the gross margin for Q1 2026 was an impressive 79.99%, indicating strong profitability potential. However, the main risk is the net loss of $28.11 million reported in Q2 2026, which raises concerns about financial sustainability.
CTXR 股價於 Tuesday 收在 $0.57，此前下跌 -1.91%
Citius Pharmaceuticals Inc (CTXR) last closed at $0.5691, losing -1.91%. These facts feed the 1-day and 1-week CTXR price prediction above.
分析師一致預期
Citius Pharmaceuticals Inc（CTXR）：買進 1、持有 0、賣出 0。展望：Strong Buy。
Sell / Buy
Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.
預測驅動因素
Citius Pharmaceuticals Inc（CTXR）的預測驅動因素綜合了相似的圖表形態、季節性與移動平均線。
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
相似圖表形態
近期走勢與 CTXR 最接近的股票，依相似度排序。
CTXR 季節性分析
Historically the probability of a positive September return for CTXR is 0.00%. April offers the highest probability of a positive month at 28.12%, while May is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。